Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jso.24798 | DOI Listing |
Publication Analysis
Top Keywords
erratum 21-gene
4
21-gene assay
4
assay core
4
core needle
4
needle biopsies
4
biopsies choose
4
choose neoadjuvant
4
neoadjuvant therapy
4
therapy breast
4
breast cancer
4
Similar Publications
Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis.
Breast Cancer Res
November 2024
Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 712 Eonjuro, Gangnam-gu, Seoul, 06273, Republic of Korea.
Erratum to "Thyroid Tumor: Investigating MicroRNA-21 Gene Suppression in FTC and FTA".
Cancer Inform
October 2020
[This corrects the article DOI: 10.1177/1176935120948474.].
View Article and Find Full Text PDFErratum: Re: Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. Journal of Surgical Oncology 2017;115(8):917-923.
J Surg Oncol
September 2018
Genomic Health, Inc., Redwood City, California.
Erratum: Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
NPJ Breast Cancer
July 2018
2Genomic Health, Inc., Redwood City, CA USA.
[This corrects the article DOI: 10.1038/npjbcancer.2016.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!